JAYPIRCA^®(pirtobrutinib)ELI LILLYHK Reg. No. HK-68865, HK-68866 (08 Oct, 2025)

Composition:³

• Each film-coated tablet contains 50/100 mg of pirtobrutinib

Indication:³

• JAYPIRCA^® as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton tyrosine kinase (BTK) inhibitor

• JAYPIRCA^® as monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who have been previously treated with a BTK inhibitor

References

3. EMA. Jaypirca Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/jaypirca-epar-product-information_en.pdf. [Accessed 18 November 2025].